Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Tough-to-Treat blood cancers

NCT ID NCT02500407

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a drug called mosunetuzumab, given alone or with another drug (atezolizumab), in people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to treatment. The goal is to find the best dose and check safety and effectiveness. About 713 adults are taking part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mosunetuzumab (with or without atezolizumab)
What this could lead to
If successful, this could offer a new treatment option for people with certain blood cancers that have not responded to prior therapies.
What could go wrong
This is an early-phase trial, so safety and effectiveness are not yet proven. Side effects may occur, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

713 people

The number who actually took part.

Started

Sep 2015

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * B-cell hematologic malignancies expected to express the cluster of differentiation 20 (CD20) antigen who have relapsed after or failed to respond to at least one prior treatment regimen and for whom there is no available therapy expected to improve survival * Adequate hepatic, hematologic, and renal function Key Exclusion Criteria: * Pregnant or lactating women * Monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, chemotherapy, or other investigational anti-cancer agent within 4 weeks prior to study drug * Treatment with radiotherapy within 2 weeks prior to the first BTCT4465A (Mosunetuzumab) administration * Systemic immunosuppressive medication within 2 weeks prior to study drug * Autologous stem cell transplantation (SCT) within 100 days prior to study drug, or any prior allogeneic SCT or solid organ transplantation * Autoimmune disease with the exception of controlled/treated hypothyroidism, disease-related immune thrombocytopenic purpura, or hemolytic anemia * History of central nervous system (CNS) lymphoma or other CNS disease * Significant cardiovascular or pulmonary disease * Hepatitis B or C or human immunodeficiency virus (HIV) * Receipt of a live attenuated vaccine within 4 weeks prior to study drug * Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days before first BTCT4465A (Mosunetuzumab) administration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphocytic leukemia, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphocytic leukemia, chronic Lymphoma, non-Hodgkin

Contacts and locations

Locations

  • Barts Cancer Institute

    London, EC1A 7BE, United Kingdom

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Hospital Universitario La Paz

    Madrid, 280146, Spain

  • Hospital Universitario Vall d Hebron

    Barcelona, 08035, Spain

  • Icon Cancer Care South Brisbane

    South Brisbane, Queensland, 4101, Australia

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Klinikum der Universität München, Campus Großhadern

    München, 83177, Germany

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center - Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center at Westchester

    Harrison, New York, 10604, United States

  • Monash Health Clinical Trial Pharmacy department

    Clayton, Victoria, 3168, Australia

  • New York Uni Medical Center

    New York, New York, 10016, United States

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, 4102, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • Rocky Mountain Cancer Center

    Denver, Colorado, 80218, United States

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, 7000, Australia

  • Royal Marsden Hospital;Institute of Cancer Research

    Sutton, SM2 5PT, United Kingdom

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Sansum Medical Clinic, Inc.

    Santa Barbara, California, 93105, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, South Australia, 3065, Australia

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Perth Blood Institute

    Nedlands, Western Australia, 6009, Australia

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, 55101, Germany

  • Universitatsklinikum Koln

    Cologne, 50931, Germany

  • University of California San Diego Moores Cancer Center

    La Jolla, California, 92093-0698, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19103, United States

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Willamette Valley Cancer Insitute and Research Center

    Springfield, Oregon, 97477, United States

  • Yale University School Of Medicine

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.